Different Methylation of CpG-SNPs in Behcet's Disease.


Journal

BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173

Informations de publication

Date de publication:
2019
Historique:
received: 18 01 2019
revised: 04 05 2019
accepted: 07 05 2019
entrez: 22 6 2019
pubmed: 22 6 2019
medline: 18 12 2019
Statut: epublish

Résumé

We recently performed an Epigenome-Wide Association Studies (EWAS) study in Behcet's disease (BD) and identified various cytosine-phosphate-guanine (CpG) loci that were aberrantly methylated. In the current study, we wanted to investigate whether these sites contained genetic polymorphisms and whether the frequency of these polymorphisms was altered in BD. A two-stage study was performed. The first stage involved 358 BD patients and 704 healthy controls to investigate genetic variants of 10 CpG-SNPs (rs10454134, rs176249, rs3808620, rs10176517, rs11247118, rs78016579, rs9461624, rs10492166, rs34929465, and rs6507921) using an iPLEX Gold genotyping assay and a Sequenom MassARRAY. In the second stage, an additional 172 independent BD patients and 330 healthy individuals are to confirm trends found in the first stage. A higher frequency of both the rs10454134 AG genotypes (p = 0.008, OR = 1.413, 95% CI = 1.094-1.826) and a lower GG genotype frequency (p = 0.003, OR = 0.630, 95% CI = 0.465-0.854) were found in BD patients compared to the controls in the first stage. However, after correcting for multiple comparisons, all associations identified in the first stage lost statistical significance. The frequencies of the other CpG-SNPs investigated were not different between BD patients and controls. The second stage was designed using an additional cohort to confirm the association with CpG-SNP, rs10454134. The data failed to confirm the association between this CpG-SNP and BD. This study did not show an association between BD and CpG-SNPs in gene sites that were earlier shown to be aberrantly methylated.

Identifiants

pubmed: 31223615
doi: 10.1155/2019/3489305
pmc: PMC6541967
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3489305

Références

FEBS Lett. 2005 Oct 31;579(26):5889-98
pubmed: 16162337
Ophthalmology. 2008 Feb;115(2):312-318.e4
pubmed: 17692378
Ocul Immunol Inflamm. 2009 Jul-Aug;17(4):249-56
pubmed: 19657978
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380
Science. 1991 Jan 11;251(4990):186-9
pubmed: 1987636
Genome Res. 2010 Jul;20(7):883-9
pubmed: 20418490
Int J Cancer. 2011 Oct 1;129(7):1689-98
pubmed: 21105050
J Mol Biol. 2011 May 27;409(1):47-53
pubmed: 21295585
Genes Dev. 2011 May 15;25(10):1010-22
pubmed: 21576262
Nucleic Acids Res. 2012 Jan;40(Database issue):D930-4
pubmed: 22064851
Nat Rev Genet. 2012 Jan 04;13(2):97-109
pubmed: 22215131
Nat Rev Genet. 2012 May 29;13(7):484-92
pubmed: 22641018
Diabetologia. 2013 May;56(5):1036-46
pubmed: 23462794
Nat Rev Genet. 2013 Aug;14(8):585-94
pubmed: 23817309
Arthritis Rheumatol. 2014 Jun;66(6):1648-58
pubmed: 24574333
Prog Mol Biol Transl Sci. 2015;134:283-98
pubmed: 26310161
Schizophr Bull. 2016 Jul;42(4):1018-26
pubmed: 26656881
Nucleic Acids Res. 2016 Jan 4;44(D1):D877-81
pubmed: 26657631
BMC Genomics. 2016 Jun 22;17:469
pubmed: 27334613
PLoS One. 2016 Jun 30;11(6):e0158475
pubmed: 27362941
Hum Genomics. 2016 Jul 25;10 Suppl 2:21
pubmed: 27461004
Biomed Res Int. 2017;2017:1274960
pubmed: 28589131
Oncotarget. 2017 Apr 19;8(31):51277-51287
pubmed: 28881647
Oncotarget. 2017 Jul 22;8(38):64263-64272
pubmed: 28969068
J Cell Biochem. 2018 Aug;119(8):6614-6622
pubmed: 29719061
Immunol Lett. 2018 Nov;203:15-20
pubmed: 29990515
Reumatol Clin. 2018 Jul 31;:null
pubmed: 30076035
Rheumatology (Oxford). 2019 Mar 12;:null
pubmed: 30863869
Mol Cell Biol. 1994 Aug;14(8):5487-94
pubmed: 7518564

Auteurs

Yang Huang (Y)

The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.

Handan Tan (H)

The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.

Qingfeng Cao (Q)

The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.

Gangxiang Yuan (G)

The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.

Guannan Su (G)

The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.

Peizeng Yang (P)

The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology and Chongqing Eye Institute, Chongqing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH